Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesenchymal stem cell conditioned medium for lung diseases
jRCT1051220090Recruiting
- Sponsor
- Seihoku Clinic
- Start
- Aug 2022
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Open-label, single-arm trial of ACT-20-CM in diffuse panbronchiolitis (DPB), interstitial lung disease (ILD), chronic obstructive pulmonary disease (COPD) and 1 more, sponsored by Seihoku Clinic. Primary endpoints: Change in KL-6, Change in high-sensitivity C-reactive protein and 5 more. Started Aug 2022; status: recruiting.
02
Drugs
ACT-20-CM
03
Conditions
diffuse panbronchiolitis (DPB)interstitial lung disease (ILD)chronic obstructive pulmonary disease (COPD)pulmonary diseases
Beyond the preview
Go deeper on jRCT1051220090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1051220090.